

## Strong backbook surplus; new business growth to pick up

Life Insurance > Result Update > May 28, 2025 CMP (Rs): 871 | TP (Rs): 1,100

LIC delivered an in-line Q4FY25 performance, with healthy VNB margin at 18.75% (Emkay: 17.9%). However, APE at Rs188.5bn declined 11% YoY albeit broadly in sync with our estimate. Share of Non-Par products in the Individual APE mix increased to ~28% for FY25 vs 18% for FY24. Going forward, the management remains optimistic about APE growth, which is likely to be largely driven by an increase in ticket size, whereas policy growth would remain subdued. With continued focus on expanding non-par share, the management has plans to expand the VNB margin, which though would be offset by APE growth, given the company's goal of driving absolute VNB growth. To bake in the Q4 developments, we tweak our FY26-27 estimates which results in a ~1-2% cut in VNB estimate. We retain ADD with unchanged Mar-26E TP of Rs1,100, implying ~FY27E P/EV of 0.7x.

#### In-line performance; lower opex, strong backbook surplus drive higher PAT

During FY25, APE at Rs568.3bn was flat YoY and in line with our estimate. However, Q4FY25 APE at Rs188.5bn witnessed 11% decline, although falling in line with our estimate. Driven by higher share of non-par products and better product-level margin, VNB margin for FY25 stood at 17.6% vs our estimate of 17.3%, whereas Q4FY25 VNB margin at 18.75% was higher than our estimate of 17.9%. Resultantly, VNB for FY25 at Rs100.1bn (up 4.5% YoY) was 1.8% ahead of our estimate, whereas Q4 VNB at Rs35.3bn was 5% higher than our expectations. EV at Rs7,769bn grew ~7% YoY, missing our estimate by 4.5% on account of impact of the negative economic variance. Driven by lower employee expense (owing to wage revision in Q4FY24) and strong backbook surplus generation, PAT at Rs481.5bn for FY25 grew 18.3% YoY, coming in higher than our estimate of Rs400bn. 13M persistency saw YoY decline, impacted by modification of products during FY24.

#### Balancing VNB margin and APE growth to drive VNB growth

The mgmt remains committed to its strategic focus of expanding non-par products for driving higher profitability and increasing the offerings available to customers. While APE growth during FY25 was impacted by increase in the minimum ticket size of policies, the management remains optimistic about growth being driven by increase in the ticket size. The mgmt has already seen some green shoots with higher acceptance of the minimum ticket-size culture. While VNB margin is likely to expand with focus on non-par products, the mgmt plans balancing the VNB margin with APE growth, driving growth in absolute VNB. The mgmt expects significant improvement in persistency going forward, given the corrective actions over the last 1-2Y that include increase in the minimum ticket size.

#### We maintain ADD with unchanged Mar-26E TP of Rs1,100

To bake in the Q4 developments, we tweak our FY26-27 estimates which leads to ~1-2% cut in APE and a  $\sim$ 10bps increase in VNB margin resulting in a  $\sim$ 1-2% cut in VNB. We introduce FY28 estimates and maintain ADD on the stock with unchanged Mar-26E TP of Rs1,100, implying FY27E P/EV of 0.7x.

LIC: Financial Snapshot (Standalone)						
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E	
GWP	4,757,519	4,888,489	5,205,132	5,606,247	6,038,901	
APE	569,700	568,280	611,700	669,220	730,176	
VNB	95,830	100,110	112,752	126,616	141,709	
VNB margin (%)	16.8	17.6	18.4	18.9	19.4	
APE growth (%)	0.5	(0.2)	7.6	9.4	9.1	
VNB growth (%)	4.7	4.5	12.6	12.3	11.9	
Adj. EPS (Rs)	64.3	76.1	78.9	87.0	95.4	
EV	7,273,440	7,768,750	8,626,892	9,559,966	10,572,300	
EVOP	669,780	826,200	871,992	957,782	1,049,968	
Op. RoEV (%)	11.5	11.4	11.2	11.1	11.0	
EVPS (INR)	1,150.0	1,228.3	1,363.9	1,511.5	1,671.5	
P/EV (x)	0.8	0.7	0.6	0.6	0.5	
P/EVOP (x)	8.1	6.6	6.2	5.7	5.2	


Source: Company, Emkay Research

Target Price - 12M	Mar-26
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	26.3

Stock Data	LICI IN
52-week High (Rs)	1,222
52-week Low (Rs)	715
Shares outstanding (mn)	6,325.0
Market-cap (Rs bn)	5,511
Market-cap (USD mn)	64,571
Net-debt, FY26E (Rs mn)	NA
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	941.5
ADTV-3M (USD mn)	11.0
Free float (%)	3.5
Nifty-50	24,826.2
INR/USD	85.3
Shareholding, Mar-25	
Promoters (%)	96.5
FPIs/MFs (%)	0.1/1.3

Price Performance						
(%)	1M	3M	12M			
Absolute	10.1	17.6	(15.9)			
Rel. to Nifty	6.6	6.8	(22.3)			

# 1-Year share price trend (Rs)



Avinash Singh avinash.singh@emkayglobal.com +91-22-66121327

## Mahek Shah

mahek.shah@emkayglobal.com +91-22-66121218

Exhibit 1: LIC - FY25 / Q4FY25 Financial Performance

(Rs bn)	FY25	FY24	YoY chg	FY25E	Variance	Q4FY25	Q4FY24	YoY chg	Q4FY25E	Variance
Individual APE	382.2	384.3	-0.6%			136.1	149.3	-8.9%		
Par	276.4	313.9	-12.0%			98.4	111.9	-12%		
Non-Par	105.8	70.4	50.3%			37.7	37.4	1%		
Group APE	186.1	185.4	0.4%			52.5	62.5	-16%		
TOTAL APE	568.3	569.7	-0.2%	567.7	0.1%	188.5	211.8	-11.0%	188.0	0.3%
Value of New Business (Net)	100.1	95.8	4.5%	98.3	1.8%	35.3	36.5	-3.0%	33.6	5.3%
VNB Margin	17.6%	16.8%	0.8ppts	17.3%	0.3ppts	18.7%	17.2%	1.5ppts	17.9%	1 ppts
Total New Business Premium	2,267.9	2,226.7	1.8%			687.5	751.7	-8.5%		
Renewal Premium	2,620.6	2,530.8	3.5%			791.4	773.7	2.3%		
Gross Premium	4,888.5	4,757.5	2.8%			1478.9	1,525.4	-3.1%		
PAT	481.5	406.8	18.4%	400.3	20.3%	190.1	137.6	38.1%	108.9	74.6%
AUM	54,523	51,219	6.5%	54,915	-0.7%					
Embedded Value	7,769	7,273	6.8%	8,132	-4.5%					
SH Equity	1,261.9	819.4	54.0%							
Persistency Ratio										
13 <sup>th</sup> month	74.8%	77.7%	-2.8 ppts							
61 <sup>st</sup> month	63.1%	60.9%	2.2 ppts							
Commission Ratio (% of WTP)	23.3%	24.0%	-1 ppts							
Expense of Management Ratio (% of WTP)	32.7%	44.5%	-12 ppts							
Solvency Ratio	211.0%	198.0%	13.0 ppts							


Source: Company, Emkay Research

**Exhibit 2: Change in estimates** 

(Rs bn)	FY26E			FY27E			FY28E		
	Old	Revised	% Change	Old	Revised	% Change	Old	Revised	% Change
APE	624	612	-1.9	676	669	-1.0	NA	730	NM
VNB	115	113	-1.6	127	127	-0.7	NA	142	NM
VNB margin (%)	18.4	18.4	0.1ppts	18.9	18.9	0.1ppts	NA	19.4	NM
EVOP	837	872	4.2	913	958	4.9	NA	1,050	NM
EV	8,557	8,627	0.8	9,467	9,560	1.0	NA	10,572	NM
PAT	416	499	20.0	447	551	23.1	NA	603	NM


# **Story in Charts**

Exhibit 3: APE growth flat YoY during FY25




Source: Company, Emkay Research

Exhibit 4: Increase in non-par mix drives healthy margins




Source: Company, Emkay Research

**Exhibit 5: Commission and opex ratios moderate sequentially** 




Source: Company, Emkay Research

Exhibit 6: AUM growth slows down sequentially, impacted by market volatility



Source: Company, Emkay Research

Exhibit 7: 13M persistency declines owing to corrective actions...



Source: Company, Emkay Research

Exhibit 8: ...while 61M persistency witnesses improvement






Exhibit 9: We expect LIC's APE growth to range at  $\sim 8-9\%$  over FY26-28E




Source: Company, Emkay Research

Exhibit 10: We expect LIC's VNB margin to expand gradually over FY26-28E




Source: Company, Emkay Research

Exhibit 11: We expect LIC's EV to grow to Rs10.6trn by FY28E



Source: Company, Emkay Research

Exhibit 12: We expect LIC's PAT to grow to Rs499bn in FY26E



# **Earnings Conference Call Highlights**

- While the total number of agents stood at ~1.49mn, LIC logged net addition of over 72,000 agents during FY25 which led to market share of 47.6% based on the number of agents.
- The management remains confident that the strategic initiatives, innovation, and digital transformation will lead to continued growth and profitability for LIC.
- The corporation saw a dip in APE growth during Q3FY25. The de-growth was partially owing to the Par segment, on account of increasing the ticket size, given implementation of the new product regulations.
- The acceptance of a higher minimum ticket-size has been well-absorbed by market participants, with the management observing encouraging engagement and adaptability from key market forces.
- Among product segments, Non-Par offerings continue to deliver the highest margin, followed by Par products. VNB margin for the individual business currently stands at ~21%. The management acknowledges that such margins are subject to change, depending on the corporation's evolving strategic priorities.
- Since its IPO, LIC has taken a measured and objective approach toward product modification and redesign. The tangible outcome of the efforts made in FY23-24 have stated materializing, thus impacting the 13<sup>th</sup> month persistency.
- The Non-Par segment has demonstrated slightly better persistency compared with the Par business. The decline in the 49<sup>th</sup> month persistency is primarily attributable to the Covid-impacted policy cohort.
- The previous year included a wage revision, which elevated employee expenses. In contrast, absence of a similar revision this year has resulted in comparatively lower employee costs.
- While open architecture may not be the most advantageous model, given the significant time and effort required to build a strong captive distribution network, the management is prepared for such a scenario. It believes that its agents will continue to demonstrate loyalty to the corporation, supported by the comprehensive social and financial benefits that the company offers, including gratuity and other welfare schemes.
- The management remains committed to driving growth in the Non-Par segment, given 1) continued emphasis on profitability, and 2) expansion of product offerings. It sees substantial headroom for growth in this segment and is confident in its long-term potential.
- VNB margin has been steadily improving with each quarter, including in the Par business. However, the management believes it is important to not look at margin alone and that growth also needs to be balanced. The main focus is to achieve healthy VNB growth.
- Rider attachment rates are currently modest, albeit showing improvement. The management is actively working to increase the take-up rate for riders and is focused on strengthening this aspect of the business.

### **LIC: Standalone Financials and Valuations**

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Gross premium	4,757,519	4,888,489	5,205,132	5,606,247	6,038,901
Net premium	4,750,696	4,881,482	5,197,671	5,598,211	6,030,245
Investment income	3,639,439	3,926,234	4,110,962	4,413,197	4,718,500
Other income	146,613	33,767	36,779	27,245	20,572
Total revenue	8,536,748	8,841,482	9,345,411	10,038,653	10,769,317
Commission expense	259,591	253,088	265,694	278,230	289,773
Operating expense	481,217	354,152	418,305	439,344	461,189
Benefits paid (net)	3,888,093	4,163,547	4,346,272	5,313,416	5,647,439
Change in reserves	3,530,361	3,533,343	3,763,990	3,429,666	3,765,250
Total expenses	8,189,663	8,362,362	8,880,250	9,550,910	10,258,386
Surplus/Deficit	347,085	479,120	465,161	487,743	510,930
Trf from policyholders acct	374,554	473,234	465,161	487,743	510,930
Shareholders' results	33,318	8,278	43,853	74,029	104,539
PBT	407,872	481,512	509,014	561,772	615,469
Extraordinary items	-	-	-	-	-
Tax expense	1,114	0	10,180	11,235	12,309
Minority interest	-	-	-	-	-
Income from JV/Associates	-	-	-	-	-
Reported PAT	406,758	481,512	498,833	550,537	603,160
PAT growth (%)	11.8	18.4	3.6	10.4	9.6
Adjusted PAT	406,758	481,512	498,833	550,537	603,160
Diluted EPS (Rs)	64.3	76.1	78.9	87.0	95.4
Diluted EPS growth (%)	11.8	18.4	3.6	10.4	9.6
DPS (Rs)	7.0	6.0	18.0	19.7	21.8
Dividend payout (%)	15.5	15.8	25.0	25.0	25.0
Effective tax rate (%)	0.3	0	2.0	2.0	2.0
Shares outstanding (mn)	6,325	6,325	6,325	6,325	6,325

Source: Company, Emkay Research

Miscellaneous Metrics	;				
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
APE	569,700	568,280	611,700	669,220	730,176
VNB	95,830	100,110	112,752	126,616	141,709
VNB margin (%)	16.8	17.6	18.4	18.9	19.4
APE growth (%)	0.5	(0.2)	7.6	9.4	9.1
VNB growth (%)	4.7	4.5	12.6	12.3	11.9
Operating ratios (%)					
NB commission/APE	0.9	1.3	1.7	1.8	1.8
Commissions/TWRP	8.4	8.0	8.0	8.0	8.0
Total exp ratio/TWRP	23.9	19.1	20.7	20.7	20.6
Conservation ratio	89.8	89.7	90.3	90.3	90.3
Solvency ratio	198.0	211.0	216.9	217.2	218.7
ROE	63.8	46.3	34.3	29.6	26.2
Historical metrics					
APE mix (%)	FY24	FY25	FY26E	FY27E	FY28E
A. Retail protection	-	-	-	-	-
B. Group protection	-	-	-	-	-
C. Savings - individual	-	-	-	-	-
Par	55.1	48.6	0	0	0
Non-Par	12.4	18.6	0	0	0
ULIP	-	-	-	-	-
D. Group Savings	32.5	32.7	0	0	0
Persistency ratios (%)	-	-	-	-	-
13th Month	77.7	74.8	0	0	0
49th Month	66.3	61.5	0	0	0

Source: Company, Emkay Research

<b>Balance Sheet</b>					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	63,250	63,250	63,250	63,250	63,250
Reserves & Surplus	757,401	1,200,958	1,585,658	2,011,486	2,477,012
Net worth	820,651	1,264,208	1,648,908	2,074,736	2,540,262
Borrowings	-	-	-	-	-
Policy liabilities	43,953,253	47,355,804	51,101,663	54,594,329	58,413,669
Provision for linked liab	348,761	475,331	512,930	547,987	586,324
FFA	12,147	18,284	21,941	26,329	31,595
Current liab and provison	634,945	486,897	450,297	434,538	416,885
Total liabilities & Equity	52,220,383	55,751,546	60,448,606	64,896,290	69,760,307
Shareholders' Investment	637,440	1,040,258	1,317,262	1,657,925	2,030,345
Policyholder Investment	48,765,124	51,362,788	55,425,601	59,213,797	63,356,308
Assets to cover linked liab.	352,578	483,120	521,335	556,967	595,931
Current assets	1,857,033	2,032,866	2,204,135	2,366,310	2,543,667
Total Assets	52,220,383	55,751,546	60,448,606	64,896,290	69,760,307
BV/Share (INR)	129.7	199.9	260.7	328.0	401.6
EV/share (INR)	1,150.0	1,228.3	1,363.9	1,511.5	1,671.5
EVOP/share (INR)	107.2	132.2	139.5	153.2	168.0
Embedded value	7,273,440	7,768,750	8,626,892	9,559,966	10,572,300
ANW	694,430	1,202,580	1,587,563	2,013,392	2,478,917
VIF	6,579,020	6,566,170	7,039,328	7,546,574	8,093,382
VIF share in EV (%)	90.5	84.5	81.6	78.9	76.6
Total AUM	51,302,935	54,783,970	59,321,891	63,637,783	68,357,252
Investment yield (%)	8.0	7.8	7.6	7.6	7.6
Yield on PH funds (%)	8.0	7.8	7.6	7.6	7.6
Yield on SH funds (%)	7.9	7.1	7.0	7.0	7.0

Source: Company, Emkay Research

Valuation & key ratio	s				
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	13.5	11.4	11.0	10.0	9.1
P/B (x)	6.7	4.4	3.3	2.7	2.2
P/EV (x)	0.8	0.7	0.6	0.6	0.5
P/EVOP (x)	8.1	6.6	6.2	5.7	5.2
Implied P/VNB (x)	(18.4)	(22.6)	(27.6)	(32.0)	(35.7)
Dividend yield (%)	0.8	0.7	2.1	2.3	2.5
EV account and RoEV					
Opening EV	5,822,430	7,273,440	7,768,750	8,626,892	9,559,966
Premium unwind	521,980	700,930	729,240	801,166	878,259
VNB	95,830	100,110	112,752	126,616	141,709
Operating variance	51,970	25,160	30,000	30,000	30,000
EVOP	669,780	826,200	871,992	957,782	1,049,968
Investment variance	954,640	(292,940)	100,000	100,000	100,000
Capital movement	(173,410)	(37,950)	(113,850)	(124,708)	(137,634)
Other changes	0	0	0	0	0
Closing EV	7,273,440	7,768,750	8,626,892	9,559,966	10,572,300
Change in EV	1,451,010	495,310	858,142	933,074	1,012,334
RoEV (%)	27.9	7.3	12.5	12.3	12.0
Operating RoEV (%)	27.9	7.3	12.5	12.3	12.0
EVOP growth (%)	13.7	23.4	5.5	9.8	9.6
EV growth (%)	24.9	6.8	11.0	10.8	10.6
Core operating RoEV (%)	23.0	22.7	22.4	22.2	22.0
Unwind rate (%)	9.0	9.6	9.4	9.3	9.2
VNB-to-opening EV (%)	1.6	1.4	1.5	1.5	1.5

#### **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
14-May-25	822	1,100	Add	Avinash Singh
09-May-25	787	1,100	Add	Avinash Singh
24-Apr-25	815	1,100	Add	Avinash Singh
03-Apr-25	815	1,100	Add	Avinash Singh
12-Feb-25	782	1,100	Add	Avinash Singh
09-Feb-25	816	1,100	Add	Avinash Singh
12-Jan-25	840	1,150	Add	Avinash Singh
16-Dec-24	924	1,150	Add	Avinash Singh
10-Nov-24	915	1,150	Add	Avinash Singh
13-Oct-24	949	1,150	Add	Avinash Singh
04-Oct-24	971	1,150	Add	Avinash Singh
09-Sep-24	1,029	1,250	Add	Avinash Singh
15-Aug-24	1,027	1,250	Add	Avinash Singh
09-Aug-24	1,133	1,250	Add	Avinash Singh
04-Jul-24	1,010	1,200	Add	Avinash Singh
10-Jun-24	997	1,200	Add	Avinash Singh
05-Jun-24	941	1,200	Add	Avinash Singh
01-Jun-24	1,013	1,200	Add	Avinash Singh
29-May-24	998	1,200	Add	Avinash Singh
10-May-24	911	1,200	Add	Avinash Singh

Source: Company, Emkay Research

#### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk D

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 28, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

#### Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of May 28, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 28, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.